Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

Baird Cuts MGI Pharma to Neutral from Outperform

Robert W. Baird cut its investment opinion on MGI Pharma, INC (MOGN) to neutral from outperform.

Analyst Christopher Raymond said that on the surface MGI Pharma's third quarter number appears essentially in line with his estimates. The non-GAAP earnings per share is just a penny shy of his estimate, while the Aloxi business is in line with his just-lowered estimate. But he's less impressed with the company's operational progress, as its cash flow swung back into negative territory, which has implications for 2006 and beyond. He thinks a few quarters of consistent operational execution will be required before he recommends the stock. As such, he's moving to the sidelines on MGI and cut his 62 cents 2006 earnings per share estimate to 29 cents.

blog comments powered by Disqus